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Abstract:
Purpose: The tumor growth kinetics of the human LoVo colorectal xenograft
model was assessed in response to vandetanib, an orally available receptor
tyrosine kinase inhibitor, radiotherapy (RT) or irinotecan (CPT-11), as single
therapies and in combination.
Methods and Materials: LoVo cells were injected subcutaneously into the
right hind limb (5 x 106 cells in 100 µl PBS) of athymic NCR NUM mice and
tumors were grown to a volume of 200-300 mm3 before treatment.
Vandetanib was administered at 50 mg/kg daily p.o. for 14 days starting on
day 1. RT was given as three fractions (3 x 3 Gy) on days 1, 2 and 3. CPT-
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11 was given at 15 mg/kg i.p. on days 1 and 3.

Tumor volumes were

measured on a daily basis and calculated by measuring tumor diameters with
digital calipers in two orthogonal dimensions.
Results: All three single treatments (vandetanib, CPT-11 and radiation)
significantly slowed LoVo colorectal tumor growth. Vandetanib significantly
increased the antitumor effects of CPT-11 and radiation, when given in
combination with either of these treatments. These treatment combinations
resulted in a slow tumor growth rate during the two weeks of vandetanib
administration. The triple combination of vandetanib, CPT-11, and radiation
produced the most marked improvement in response as observed by
measurable shrinkage of tumors during the first week of treatment.
Conclusions: The tumor growth delay kinetics observed in this study of the
LoVo colorectal model suggest concurrent and sustained post-sequencing of
vandetanib with cytotoxic therapy may be beneficial in tumors of this type.
Key Words:
Vandetanib, radiotherapy, CPT-11, LoVo colorectal cancer, angiogenesis
inhibitor

Introduction
Colorectal cancer (CRC) remains one of the leading causes of mortality
worldwide. In recent years, the most widely used chemotherapy for metastatic
CRC, fluoropyrimidine (5-fluorouracil (5-FU)) in combination with folinic acid
(FA), has been combined with newer, highly active cytotoxic agents. Among
these agents is the DNA topoisomerase I inhibitor, irinotecan (CPT-11) 1, a
potent DNA-targeting drug used in patients with CRC that is refractory to
treatment with fluorouracil and leucovorin. This cytotoxic agent is, in turn,
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currently being combined with new molecular therapies targeting the tumor
vasculature and key signaling pathways controlling tumor cell proliferation,
angiogenesis and survival in CRC. In this regard, the epidermal growth factor
receptor (EGFR) plays an important role in CRC tumor growth and
progression 2, and cetuximab, a monoclonal antibody (MAB) specific for
EGFR, has been approved for use in combination with CPT-11 in patients
with EGFR-expressing CRC refractory to CPT-11-based chemotherapy 3. In
addition, bevacizumab, a MAB specific for vascular endothelial growth factor
(VEGF-A), a key player in tumor angiogenesis in CRC as well as other solid
tumors, has been approved for the treatment of metastatic CRC in
combination with intravenous 5-FU-based chemotherapies 4. Despite recent
improvements in treatment for CRC, a need still remains to improve the
performance of existing treatments and to establish the optimum scheduling
and dosing of combined therapies.

Vandetanib (ZACTIMATM) is an oral receptor tyrosine kinase inhibitor that, in
recombinant enzyme assays, demonstrates potent activity against VEGFR-2
tyrosine kinase (IC50 = 40 nmol/L) with additional activity against EGFR (IC50
= 500 nmol/L) and RET (IC50 = 130 nM) tyrosine kinases

5-8

. Vandetanib

currently has orphan-drug status in the USA and Europe for medullary thyroid
cancer (MTC) (in which RET activity is important) and is in Phase III
development in non-small-cell lung cancer and MTC. Phase II studies are
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ongoing to investigate its efficacy in other tumor types, thyroid cancer,
hepatocellular carcinoma and glioblastoma.

Vandetanib has been shown to enhance the efficacy of radiotherapy in
subcutaneous (s.c.) and orthotopic tumor xenograft models

9-13

. The

combination of vandetanib, radiation and current chemotherapeutic agents
used in CRC treatment has not been studied to date. Preclinical
demonstration of efficacy of a combination protocol with novel agents plus
radiation is usually considered crucial prior to clinical evaluation. The purpose
of the present study was to examine the effect of vandetanib on the radiation
response of a colorectal tumor model when administered in combination with
CPT-11. It was hypothesized that simultaneous inhibition of VEGFR and
EGFR by vandetanib in combination with the cytotoxic agent CPT-11 would
interact to enhance radiation response and tumor control in the human LoVo
colorectal tumor cell model. The LoVo colorectal model expresses activated
EGFR

14, 15

and is highly vascularized, and therefore is an appropriate model

to test the hypothesis.

Materials and Methods
Animal and Tumor Model: LoVo cell suspensions (5 x 106 cells in 100 µl
phosphate buffered saline) were implanted s.c. into the right hind limbs of 6-8
week-old athymic NCR NUM mice (Taconic Farms, Hudson, NY). A s.c.
xenograft model was chosen to facilitate radiation dosing and ease of tumor
6

measurements. Tumors were allowed to grow for approximately 25 days, until
reaching an approximate volume of 200-300 mm3 at the start of treatment
(day 1). All animals were randomized among treatment groups.

Drug

Treatment:

Vandetanib

(AstraZeneca,

Macclesfield,

UK)

was

administered by oral gavage (p.o.) at 50 mg/kg daily for 14 days, starting on
day 1. Vandetanib dosing in this study was based on previous
pharmacokinetic studies in mouse models predicting relevance of this dosing
to clinical drug exposure in human patients

16

. CPT-11 was given at 15 mg/kg

intraperitoneally (i.p.) on days 1 and 3.

Radiation Treatment: Irradiation was performed on anesthetized mice using
X-rays generated by a PanTak, 310 kVe x-ray machine, 0.25 mm Cu + 1 mm
Al added filtration, at 125 cGy per min. Dosimetry was performed by an inthe-beam ionization chamber calibrated against a primary standard.
Corrections were made daily for humidity, temperature and barometric
pressure. Mice were anesthetized with a combination of ketamine and
acepromazine at a concentration of 37.5 mg/kg and 0.2 mg/kg, respectively,
to provide 25-30 minutes of sedation. Each mouse was confined in a lead
casing with its tumor-bearing leg extended through an opening on the side to
allow the tumor to be irradiated locally. Radiation was administered as three
daily fractions of 3 Gy each on days 1, 2, and 3. On days when radiation was
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administered with vandetanib and/or CPT-1, vandetanib and CPT-11 were
given approximately 2 hours before radiation, with vandetanib preceding
CPT-11 administration.

Tumor Measurement: Tumors were synchronized to be approximately 250
mm3 at the start of treatment (day 1) and were measured four to five times per
week, for up to six weeks of follow-up, or until they reached 2,000 mm3.
Tumor size was determined by direct measurement with calipers and
calculated by the formula: (smallest diameter2 x widest diameter)/2. Tumors
were not allowed to grow beyond 2,000 mm3 in accordance with Institutional
Animal Care and Use Committee regulations.

In-vivo Tumor Necrosis: Tumors were collected from animals on day 14
following start of treatment for fixation and staining with H&E. The area of
necrosis was evaluated by image analysis and expressed as the percentage
of the total tumor area.

Statistical

Analysis Tumor growth was analyzed via mixed-effects

regression, as previously described The method was used because it does
not depend on an arbitrary endpoint target tumor size, but utilizes the
repeated tumor size measurements obtained over the entire study period,
while appropriately handling unbalanced data (i.e., different number of
measurements for different animals) and the correlation of each animal’s
8

measurements over time. Mixed-effects regression yields generalizable
parameters of interest (e.g., average daily tumor growth rate and tumor
doubling time), and can investigate treatment interactions and non-linear
patterns of tumor growth. The base-10 logarithm of tumor volume was
modeled as a function of time and treatment. Linear or quadratic growth
curves over time were fitted to the log-transformed data, depending on growth
patterns in each treatment groupAll statistical analyses were conducted in
SAS 9.2 (SAS Institute Inc., Cary, NC, 1999-2001).
Results
The experiment involved three different treatments (vandetanib, CPT-11, and
radiotherapy), as described above and summarized in Figure 1. Data were
collected from a total of 104 animals in eight experimental groups (11-16
animals per group) and are summarized in Figure 2. Starting tumor sizes
were comparable across groups, with geometric means ranging from 230 to
257 mm3 (p = 0.771). All treatments were well tolerated in the animals with no
observable loss of body weight.

The three single-treatment groups (CPT-11, radiation, or vandetanib), as well
as the combination of CPT-11 with radiation (Figure 2) were fitted to log
transformed curves, while the three remaining groups that received
combination treatments involving vandetanib showed a significantly non-linear
tumor growth and were fitted to quadratic curves.

9

Figure 3 shows the measured geometric mean tumor size graphically over
time. Table 1 shows the corresponding calculated tumor growth parameters
(daily tumor growth rate and tumor doubling time). Table 2 shows p-values for
group comparisons at 7, 14, and 21 days after start of treatment.

The control group had an estimated average daily tumor growth rate of 9.9%,
corresponding to an average tumor doubling time of about 7 days (Table 1).
All three single treatments resulted in a significant inhibition of tumor growth,
compared with the control group (average daily tumor growth rates: CPT-11:
7.1%, p = 0.015; radiation: 5.6%, p = 0.001; vandetanib: 5.0%, p = 0.001)
Vandetanib inhibited tumor growth significantly more than CPT-11 (p = 0.043)
but not radiation (p = 0.514); radiation and CPT-11 were not significantly
different (p = 0.139). The combination of CPT-11 with radiation produced a
daily tumor growth rate of 5.1%, which was significantly lower than CPT-11
alone (p = 0.015) but comparable to radiation alone (p = 0.560). There was no
significant (additive) interaction between CPT-11 and radiation (p = 0.105).

The remaining three groups which received treatment combinations involving
vandetanib (with either CPT-11 or radiation, or with both CPT-11 and
radiation), showed significant treatment interactions (p = 0.001 for the
interaction between vandetanib and CPT-11 and between vandetanib and
radiation) and non-linear tumor growth patterns. Compared to singletreatment groups, growth was significantly delayed (and, in the triple-
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treatment combination, tumor volume actually decreased) early on, but
progressively accelerated later, although it never exceeded that of the
untreated controls (Figure 3). Because of the non-linearity of tumor growth in
these groups, tumor growth parameters are not constant over time and
comparisons depend on the timepoint referenced. Table 2 shows p-values for
days 7, 14, and 21.

During the first week of treatment, animals receiving the combination of
vandetanib with CPT-11 had average daily tumor growth rate of less than
3.5%, significantly lower than CPT-11 alone and marginally so compared to
vandetanib alone (p = 0.001 and 0.058, respectively, after 7 days). By the end
of the two-week vandetanib treatment, the tumor growth rate in the
combination group (4.6%) was still significantly lower than for CPT-11 alone
(p = 0.015) but comparable to that for vandetanib alone (p = 0.682). By the
third and fourth weeks, tumor growth had reached levels similar to those seen
in the single-treatment groups (Figure 3, Table 1).

The combination of vandetanib with radiation resulted in a similar pattern of
non-linear tumor growth inhibition. After the first 7 days, the average daily
tumor growth rate of 2.1% was significantly lower than for either radiation
alone or vandetanib alone (p = 0.005 and 0.019, respectively). After 14 days,
the tumor growth rate in the combination group had accelerated to 3.4% and
was only marginally lower than for radiation alone and comparable to that for

11

vandetanib alone (p = 0.080 and 0.212, respectively). By the third and fourth
weeks, tumor growth had become similar to that seen in the single-treatment
groups (Figure 3, Table 1).

Despite delaying tumor growth in the initial weeks, the treatment
combinations induced only modest levels of tumor necrosis (10-20%), with no
significant differences between treatment groups (Figure 4).

The pattern of tumor growth in the group that received the triple-treatment
combination reflected both the interaction between vandetanib and CPT-11
and that between vandetanib and radiation (as mentioned previously). Thus,
during the first week, instead of the delayed tumor growth seen in the twotreatment combinations, tumor volume in the triple-treatment combination
actually decreased (p = 0.001 versus vandetanib plus CPT-11, and 0.052
versus vandetanib plus radiation). After that time, similar to the two-treatment
combinations that involved vandetanib, tumor growth started accelerating. By
the end of the third week, tumor growth in the triple-treatment combination
group was similar to that in the two-treatment combination groups involving
vandetanib, and by the fourth week, it was similar to that in the singletreatment groups.

Discussion
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Relatively little is known about the antitumor effects of combining cytotoxic
drugs, radiotherapy, and novel targeted therapies that specifically interfere
with signaling pathways controlling cancer proliferation, angiogenesis and
survival. In the present study, vandetanib, a potent inhibitor of both VEGFR
and EGFR signaling, was combined with CPT-11 and/or radiation, to
determine if greater anti-colorectal tumor activity can be obtained.

This study demonstrated that all three single treatments (vandetanib, CPT-11
and radiation) significantly slowed LoVo colorectal tumor growth. Previous
studies with single-agent vandetanib demonstrated that chronic oral
administration reduced tumor vascularity and tumor growth in a variety of
xenograft models, including CRC

7, 17

. In the clinic, the safety and tolerability

of vandetanib has been demonstrated in patients with advanced colorectal
cancer as well as other solid tumors18. Vandetanib induced manageable
normal tissue toxicities related to inhibition of EGFR and VEGFR signaling
such as diarrhea, rash and hypertension19,

20

. The effect of combining

radiation and vandetanib on normal tissue is currently unknown, however it
has been shown in both preclinical and clinical trials that use of VEGF
inhibitors with radiation may result in higher rates of normal tissue toxicity
such as induction of thrombosis, hemorrhage and bowel toxicities

21-23

. In

contrast, it was postulated that combination of radiotherapy with inhibitors of
angiogenesis may actually decrease these risks because radiotherapy has
been used to prevent hemorrhage

24

. Overall the investigation of agents such

13

as vandetanib in combination with radiation in normal tissue are lacking, and
thus will be a major focus in the future.

As previously discussed, single agent vandetanib has dual tyrosine kinase
inhibitory activity against VEGFR-2 and EGFR which allows it to target two
key pathways responsible for tumor growth, i.e., tumor angiogenic signaling
and tumor cell proliferation. It has been speculated that dual suppression may
be critical for sustained suppression of tumor growth, especially since the
EGFR and VEGFR pathways are linked and exhibit cross-talk

25

. In addition,

vandetanib can also enhance the antiproliferative activity of selective EGFR
inhibitors such as cetuximab, thereby potentiating suppression of EGFR
signaling17.

The present study confirmed that vandetanib, chronically administered over
two weeks, slowed tumor growth in a colorectal tumor model, and, under the
dosing conditions of this study, slowed tumor growth to a greater extent than
CPT-11 alone and to a similar level to radiation alone. Moreover, vandetanib
significantly increased the antitumor effects of CPT-11 and radiation, when
given in combination with either of these treatments. In particular, these
treatment combinations resulted in a slow tumor growth rate during the two
weeks of vandetanib administration. These results confirm an earlier study by
Troiani et al.

26

, in which vandetanib (25 mg/kg/day) administered in

combination with CPT-11 exhibited high antitumor activity in HT29-tumor-

14

bearing nude mice. Troiani et al. showed a correlation between this dosing
schedule and enhanced EGFR and VEGFR signal inhibition.
In the present study, the triple combination of vandetanib, CPT-11, and
radiation produced the most marked improvement in response in the LoVotumor-bearing mice. The triple treatment produced a measurable shrinkage of
tumors during the first week of treatment. The combination of vandetanib,
chemotherapy (gemcitabine), and radiation has also been previously shown
to significantly inhibit tumor progression in a pancreatic tumor model

27

.

Importantly, the present study also investigated the kinetics of tumor growth,
both during and after a course of treatment. It was demonstrated that the
addition of vandetanib significantly enhanced the initial antitumor effect of
chemo-radiation. However, when vandetanib treatment ended, tumor growth
returned to near control (untreated) levels. Therefore, these data support the
rationale of adding an anti-vascular agent to cytotoxic therapies and provide
valuable information for the design of therapeutic protocols.

The precise mechanisms leading to initial tumor regression with the combined
therapies in this study are not known. Analysis of interactions between
cytotoxic agents and vandetanib is complex, given that both the tumor cells
and the tumor microenvironment are affected. In this connection, radiation
can kill not only tumor cells but also endothelial cells of the tumor vasculature,
thereby affecting the radiosensitivity of the tumor

28, 29

. In addition, cytotoxic

agents have mechanisms of cell killing that are different from the targeted
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agent. Both radiation and CPT-11 kill cells through DNA damage. Both
chemotherapy and radiation can also alter cellular signaling pathways by
inducing EGFR phosphorylation and through the growth factor signaling
pathway, contribute to tumor cell proliferation and survival

30-32

. Preclinical

studies have also shown that cytotoxic therapy alone, such as radiation, can
result in intensification of angiogenic processes

33

. After cytotoxic treatment,

up-regulation of vascular growth factors and their receptors occurs which
contributes to tumor recurrence and progression

34

. Direct up-regulation of

VEGF after irradiation of various cancer cell lines has been reported

35

.

Radiation also induces transient tumor hypoxia which results in upregulation
of hypoxia inducible factor -1 (HIF-1) which can stimulate VEGF and VEGFR2 expression. Therefore, simultaneous inhibition of both VEGFR and EGFR
signaling through chronic administration of vandetanib in combination with
cytotoxic therapy is expected to suppress the upsurge in pro-proliferative and
angiogenic signaling resulting from CPT-11 and radiation-induced EGFR and
VEGF. This suppression will thereby lead to inhibition of vascular protective
mechanisms and growth factor mechanisms contributing to tumor regrowth.

The increased tumor growth that was seen in this study following
discontinuation of vandetanib suggests that inhibition of angiogenic and proproliferative signaling is readily reversed. The current observations are in
agreement with a number of both preclinical and clinical studies showing that
tumors can adapt to anti-angiogenic treatment by undergoing “evasive
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resistance” to angiogenesis inhibitors

36

. Mechanisms of resistance include

upregulation of alternative proangiogenic signaling pathways as well as
recruitment of bone marrow-derived proangiogenic cells

37, 38

. In addition,

administration of vandetanib itself has been observed to increase VEGF
production in certain cancer cell lines as well as in tumor xenografts

39, 40

,

thereby suggesting an additional contributing mechanism to tumor relapse.
More studies will be needed to determine whether additional angiogenic
pathways may be induced by triple modality treatment.

Conclusions
The results of this study provide a scientific rationale for testing the
combination of vandetanib, CPT-11, and radiation in patients with CRC.
Although the best schedule and sequencing for this triple modality treatment
has yet to be determined, the tumor growth delay kinetics observed in this
study suggest that improvement in colorectal tumor response can be obtained
by concurrent and sustained post-sequencing of vandetanib with cytotoxic
therapy, keeping in mind that prolonged chronic administration of the receptor
tyrosine kinase inhibitors may lead to the development of resistance and the
requirement for additional therapeutic agents as seen with other targeted
agents, such as imatinib and gefitinib 41, 42.
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Tables
Table 1. Estimates of the average daily tumor growth rate and average tumor
doubling time, by treatment group.
Table 2. P-values for comparisons of treatment groups, on days 7, 14 and 21,
after the start of treatment.
Figures
Figure 1. Summary of treatment groups.
LoVo cells were implanted s.c. into the right hind limbs of athymic NCR NUM
male mice. Mice were randomized into eight experimental groups (11-16
animals per group). Vandetanib was administered at 50 mg/kg daily p.o. for
14 days, starting on day 1. CPT-11 was given at 15 mg/kg i.p. on days 1 and
3. Radiation was given as three fractions (3 x 3 Gy) on days 1, 2, and 3.

Figure 2.

Tumor growth curves in LoVo xenografts treated with

vandetanib, CPT-11, and/or radiation.
Individual mouse data for eight treatment groups (11-16 animals per group),
along with fitted group curves. Vandetanib was administered at 50 mg/kg
daily p.o. for 14 days, starting on day 1. CPT-11 was given at 15 mg/kg i.p. on
days 1 and 3. Radiation was given as three fractions (3 x 3 Gy) on days 1, 2,
and 3.

Figure 3. Estimated geometric mean tumor volume over time in LoVo
xenografts treated with vandetanib, CPT-11, and/or radiation.
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Vandetanib was administered at 50 mg/kg daily p.o. for 14 days, starting on
day 1. CPT-11 was given at 15 mg/kg i.p. on days 1 and 3. Radiation was
given as three fractions (3 x 3 Gy) on days 1, 2, and 3.

Figure 4. H&E stained sections of LoVo colorectal xenografts.
All tumors were collected from animals on day 14 following start of treatment.
Areas of necrosis are denoted by nec. Magnification 20 X.
(A) Control (untreated) tumor, showing 2% necrosis.
(B) Tumor from animal after administration of last dose of vandetanib,
showing 15% necrosis.
(C) Tumor from animal after administration of CPT-11 and RT, showing 20%
necrosis.
(D) Tumor from animal after administration of vandetanib and CPT-11,
showing 10% necrosis.
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